Assessing immune responses after acute ischemic stroke treatment
IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy
This study is testing how the immune system reacts in patients treated for an acute ischemic stroke to see if these responses can help predict their recovery after three months.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild Research network |
| Drugs / interventions | Natalizumab |
| Locations | 1 site (Paris, Paris) |
| Trial ID | NCT04663399 on ClinicalTrials.gov |
What this trial studies
The IMPRESS study aims to evaluate the immuno-inflammatory and thrombo-inflammatory profiles of patients undergoing treatment for acute ischemic stroke with mechanical thrombectomy. It focuses on the first 24 to 36 hours post-treatment to understand how these immune responses may influence functional outcomes at three months. By identifying reliable biomarkers, the study seeks to enhance the understanding of stroke recovery and potentially guide future therapeutic interventions. This observational study will include patients who meet specific criteria related to their stroke treatment.
Who should consider this trial
Good fit: Ideal candidates are patients experiencing an acute ischemic stroke who are eligible for mechanical thrombectomy.
Not a fit: Patients who are pregnant, breastfeeding, or under legal protection measures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and targeted therapies for patients recovering from acute ischemic stroke.
How similar studies have performed: While many preclinical studies have shown promise in understanding immune responses in stroke, this specific approach in humans is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed, * Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent); * Affiliated or beneficiary of a social security scheme or equivalent. Non inclusion Criteria: * Pregnant or breast-feeding women * Patient benefiting from a legal protection measure Exclusion Criteria: None.
Where this trial is running
Paris, Paris
- Hôpital Fondation Adolphe de Rothschild — Paris, Paris, France (Recruiting)
Study contacts
- Principal investigator: Benjamin Maier, MD — Fondation Ophtalmologique Adolphe de Rothschild
- Study coordinator: Benjamin Maier, MD
- Email: bmaier@for.paris
- Phone: 0148036556
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.